- Home
- INDO vs CUE Comparison
INDO vs CUE Comparison
Compare INDO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INDO | CUE |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 49.6M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INDO | CUE |
|---|---|---|
| Price | $2.93 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 233.5K | ★ 249.2K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,293,625.00 | ★ $7,100,000.00 |
| Revenue This Year | N/A | $36.58 |
| Revenue Next Year | N/A | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.10 | $0.47 |
| 52 Week High | $7.95 | $1.75 |
Technical Indicators
Market Signals| Indicator | INDO | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 29.93 |
| Support Level | $2.60 | $0.47 |
| Resistance Level | $3.10 | $0.51 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 70.00 | 10.78 |
Price Performance
Historical ComparisonAbout INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.